- Q1 2024 SpringWorks Therapeutics Inc Earnings Call TranscriptMay 02, 2024$43.35 (-7.45%)Earnings
- SpringWorks Therapeutics Inc at JPMorgan Healthcare Conference TranscriptJan 08, 2024
- SpringWorks Therapeutics to Discuss The ReNeu Topline Data TranscriptNov 16, 2023
- SpringWorks Therapeutics Inc at Goldman Sachs Healthcare Conference TranscriptJun 12, 2023
- SpringWorks Therapeutics Inc at TD Cowen Oncology Innovation Summit (Virtual) TranscriptMay 31, 2023
- SpringWorks Therapeutics Inc at Bank of America Global Healthcare Conference TranscriptMay 09, 2023
- SpringWorks Therapeutics Inc at Cowen Health Care Conference TranscriptMar 07, 2023
- SpringWorks Therapeutics Inc at JPMorgan Healthcare Conference TranscriptJan 09, 2023
- SpringWorks Therapeutics Inc at Evercore ISI HealthCONx Conference (Virtual) TranscriptNov 29, 2022
- SpringWorks Therapeutics Inc at H.C. Wainwright Precision Oncology Conference (Virtual) TranscriptNov 14, 2022
- SpringWorks Therapeutics Inc at Goldman Sachs Global Healthcare Conference TranscriptJun 15, 2022
- SpringWorks Therapeutics Inc R&D Day (Virtual) TranscriptJun 10, 2022
- SpringWorks Therapeutics Inc To Discuss The DeFi Trial Data Call TranscriptMay 24, 2022
- SpringWorks Therapeutics Inc at Guggenheim Partners Healthcare Talks Oncology Days (Virtual) TranscriptFeb 10, 2022
- SpringWorks Therapeutics Inc and the ReNeu Trial for NF1-Related Plexiform Neurofibromas TranscriptJul 15, 2021
- SpringWorks Therapeutics Inc at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 08, 2021
- SpringWorks Therapeutics to Discuss the Reneu Trial Data and Program Update Call TranscriptFeb 25, 2021
- SpringWorks Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 12, 2021
- SpringWorks Therapeutics Inc Clinical Trials TranscriptOct 13, 2020
SpringWorks Therapeutics Inc at Evercore ISI HealthCONx Conference (Virtual) Transcript
Hey, guys. Thanks for joining us. Pleasure to have the management team from SpringWorks join us. I know there's a lot of activity coming up in the coming months but let me turn it over to you first to kick things off.
Thanks, Umer. Obviously, we appreciate you hosting us today at your conference. It's a pleasure to be here to share updates on SpringWorks ahead of -- as you said, it will be a busy 12 months ahead of us with data across the portfolio and potentially a drug launch upcoming in 2023. Before going into specific questions, I'd love to start with a brief overview of SpringWorks.
For those who don't know us, we are a clinical-stage oncology company committed to making a profound impact on patients suffering from severe rare diseases and cancer. We're advancing a diversified pipeline spanning our three core focus areas, which are rare tumors, multiple myeloma through BCMA combinations, and biomarker-defined metastatic solid tumors.
Our late-stage
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)